Kazia Therapeutics EV/EBITDA
¿Qué es el EV/EBITDA de Kazia Therapeutics?
El EV/EBITDA de Kazia Therapeutics Limited es N/A
¿Cuál es la definición de EV/EBITDA?
EV / EBITDA es el valor de la empresa dividido por las ganancias antes de intereses, impuestos, depreciación y amortización. Es una medida de cuál cara es una acción y es más frecuentemente válida para comparaciones entre compañías que la relación precio / ganancias. Mide el precio (en forma de valor empresarial) que un inversionista paga en beneficio del flujo de caja de la compañía (en forma de EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA de compañías en Sector Health Care en ASX en comparadas con Kazia Therapeutics
¿Qué hace Kazia Therapeutics?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Empresas con ev/ebitda similar a Kazia Therapeutics
- NeonMind Biosciences tiene EV/EBITDA de N/A
- Lumos Diagnostics tiene EV/EBITDA de N/A
- Bluewater Acquisition Corp tiene EV/EBITDA de N/A
- Guyana Goldstrike Inc tiene EV/EBITDA de N/A
- BrewBilt Manufacturing tiene EV/EBITDA de N/A
- Sable Resources tiene EV/EBITDA de N/A
- Kazia Therapeutics tiene EV/EBITDA de N/A
- engage:BDR tiene EV/EBITDA de N/A
- Viaan Industries tiene EV/EBITDA de N/A
- Antera Ventures Ii Corp tiene EV/EBITDA de N/A
- MacDonald Mines Exploration tiene EV/EBITDA de N/A
- Sihayo Gold tiene EV/EBITDA de N/A
- Fabled Copper tiene EV/EBITDA de N/A